HB238, titled the Healthy Technology Act of 2025, would amend the Federal Food, Drug, and Cosmetic Act to clarify that artificial intelligence and machine learning systems can be treated as a “practitioner licensed by law to administer such drug” for purposes of prescribing drugs. The bill applies only when the AI or machine learning technology is authorized by the relevant state statute to prescribe the drug and has also been approved, cleared, or authorized by the Food and Drug Administration under specified FDA pathways.
In practical terms, the bill would create a federal statutory pathway for certain AI-enabled systems to participate in prescription decisions, potentially expanding the role of automated clinical tools in healthcare delivery. It would not broadly authorize AI to prescribe on its own; instead, it ties that authority to both state law and FDA oversight, and it amends a specific provision of the Food, Drug, and Cosmetic Act governing prescription drug dispensing.
Impact
The bill would modify section 503(b) of the Federal Food, Drug, and Cosmetic Act by expanding the definition of a legally authorized practitioner to include qualifying artificial intelligence and machine learning technologies. This could affect how prescription authority is interpreted under federal law, especially for states that choose to authorize AI-assisted or AI-driven prescribing and for manufacturers seeking FDA approval or clearance for such systems. It would also potentially influence pharmacists, prescribers, regulators, and healthcare technology developers by creating a clearer legal basis for AI-enabled prescribing tools.
Sentiment
There is no recorded committee transcript or vote history in the provided materials, so the bill’s sentiment cannot be measured from debate or roll call data. Based on the text alone, the bill appears to be framed positively as a modernization measure intended to integrate emerging technology into healthcare, but no formal support or opposition is documented in the available context.
Contention
The main potential points of contention are likely to be patient safety, medical liability, and the appropriate scope of AI in clinical decision-making. Supporters would likely emphasize innovation, efficiency, and expanded access to care, while critics may question whether AI systems should ever be treated as prescribing practitioners and whether state-by-state authorization is sufficient to protect patients. Another likely issue is the interaction between federal FDA approval and state medical practice authority, since the bill requires both but does not specify operational standards for oversight or accountability.